Abstract
Magnetic hyperthermia (MH), proposed by R. K. Gilchrist in the middle of the last century as local hyperthermia, has nowadays become a recognized method for minimally invasive treatment of oncological diseases in combination with chemotherapy (ChT) and radiotherapy (RT). One type of MH is arterial embolization hyperthermia (AEH), intended for the presurgical treatment of primary inoperable and metastasized solid tumors of parenchymal organs. This method is based on hyperthermia after transcatheter arterial embolization of the tumor’s vascular system with a mixture of magnetic particles and embolic agents. An important advantage of AEH lies in the double effect of embolotherapy, which blocks blood flow in the tumor, and MH, which eradicates cancer cells. Consequently, only the tumor undergoes thermal destruction. This review introduces the progress in the development of polymeric magnetic materials for application in AEH.
Highlights
Cancer is the second leading cause of death around the world
This review introduces the progress in Kazantseva,E.N.; N.E.; Citation: Kazantseva, Magnetic Nanomaterials for Arterial the development of polymeric magnetic materials for application in AEH
19.3 milliondeaths new cancer cases were diagnosed worldnotable from this report that the number deaths cancer not change wide, with almost
Summary
Cancer is the second leading cause ofreport, death around the world. According the World diagnosed worldwide, with almost million from cancer in 2020. Despite these challenges, MFH has received approval for clinical testing in humans by the German Federal Institute for Drugs and Medical Devices and the United States Food and Drug Administration to treat glioblastoma and prostate gland by colloidal suspension of aminosilane-coated iron oxide nanoparticles (NanoTherm® , MagForce company, Berlin, Germany) [70,71,72] This is most likely due to the development of a unique inductive heating applicator operating at an AMF frequency of 100 kHz with a field strength of up 18 kA/m
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
